The Q1 earnings report for NeoGenomics (NASDAQ:NEO) was released on Tuesday, April 30, 2024 at 07:30 AM.
Here's what investors need to know about the latest announcement.
Earnings
NeoGenomics beat estimated earnings by 60.0%, reporting an EPS of $-0.02 versus an estimate of $-0.05.
Revenue was up $19.02 million from the same period last year.
Analysis of Past Earnings
Last quarter the company beat on EPS by $0.05 which was followed by a 12.0% increase in the share price the next day.
Here's a look at NeoGenomics's past performance:
| Quarter | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|
| EPS Estimate | -0.05 | -0.02 | -0.08 | -0.11 | -0.15 |
| EPS Actual | -0.02 | 0.03 | 0 | -0.05 | -0.09 |
| Revenue Estimate | 149.89M | 152.54M | 142.00M | 137.42M | 126.39M |
| Revenue Actual | 156.24M | 155.55M | 151.95M | 146.92M | 137.22M |
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Guidance
NeoGenomics management provided guidance for FY 2024, expecting earnings between $0.0 and $0.04 per share.
Recent Earnings Releases from Competitors
With NeoGenomics's earnings data in hand, it's essential to compare its metrics to those of similar companies, including BrightSpring Health, Guardant Health, and R1 RCM.
- BrightSpring Health's earnings on May 02, 2024 exceeded market projections, revealing an EPS of $0.12 compared to the estimated EPS of $0.07, resulting in a 71.43% increase.
- The latest earnings announcement from Guardant Health on May 09, 2024 exceeded expectations, with an actual EPS of $-0.46 compared to the market's estimate of $-0.85, resulting in a 45.88% increase.
- On May 08, 2024, R1 RCM unveiled earnings that were below market expectations, with an actual EPS of $-0.08 compared to an estimated EPS of $-0.01, resulting in a -700.0% decrease.
Competitors Quarterly Earnings and Stock Performance Analysis
This analysis provides insights into the market's response to the latest earnings releases of key competitors. It highlights the expected and announced earnings per share (EPS) for each company, along with the corresponding stock prices at the close of the announcement day and the open of the following trading day.
| Company Name | Date | EPS Expected | EPS Announced | EPS Change Percent | Stock Price At Close | Stock Price at Next Day Open | Price Change Percent |
|---|---|---|---|---|---|---|---|
| NeoGenomics | April 30, 2024 | -0.05 | -0.0260.0% | $13.92 | $14.0 | 0.57% | |
| BrightSpring Health | May 02, 2024 | 0.07 | 0.1271.43% | $11.06 | $11.27 | 1.9% | |
| Guardant Health | May 09, 2024 | -0.85 | -0.4645.88% | $19.44 | $21.84 | 12.35% | |
| R1 RCM | May 08, 2024 | -0.01 | -0.08-700.0% | $12.84 | $12.67 | -1.32% |
Analyzing Peer Revenue Discrepancy: Estimated vs. Announced
The comparison table below presents estimated and announced revenue figures for NeoGenomics's peers. This comparison provides insights into the revenue performance of these companies, offering valuable context for understanding their financial standing within the industry.
| Company Name | Estimated Revenue | Announced Revenue | Revenue Surprise Percentage |
|---|---|---|---|
| NeoGenomics | 149.89M | 156.24M | 4.24% |
| BrightSpring Health | 2.31B | 2.58B | 11.56% |
| Guardant Health | 150.67M | 168.49M | 11.83% |
| R1 RCM | 611.93M | 603.90M | -1.31% |
To track all earnings releases for NeoGenomics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.